Boehringer Ingelheim

For Healthcare Professionals

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Therapeutic Area
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.

Section Overview

Therapeutic Area

Section Overview

Oncology

Inflammation

Respiratory
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

See All Products

Products

See All Products
Resources
Contact
Logout

Boehringer Ingelheim

Glyxambi
Prescribing information
Voice of CRM
Heart Failure Got Treatment
Champs Opens in new tab
Prof Merlin Thomas CKD Video Series
Prof Christoph Wanner’s take on EMPA-KIDNEY
Videos
Let's Talk

JARDIANCE^® provides triple protection in your patients with CRM conditions:

LET's TALK

PTPHF||What makes SGLT2i an ideal HF therapy?

3:50

PTPHF||What makes SGLT2i an ideal HF therapy?

Watch now Opens in new tab

PTPHF||What is the role of empagliflozin in patients hospitalized for heart failure?

4:27

PTPHF||What is the role of empagliflozin in patients hospitalized for heart failure?

Watch now Opens in new tab

$PTPHF||What do we know about the consistency of the results for empagliflozin across the spectrum of ejection fraction?$

2:48

PTPHF||What do we know about the consistency of the results for empagliflozin across the spectrum of ejection fraction?

Watch now Opens in new tab

PTPHF||What is the impact on the treatment landscape from the early benefits seen in the EMPEROR trials?

2:26

PTPHF||What is the impact on the treatment landscape from the early benefits seen in the EMPEROR trials?

Watch now Opens in new tab

PTPHF||How has the HFpEF guidelines evolved with the advent of SGLT2i trials?

4:22

PTPHF||How has the HFpEF guidelines evolved with the advent of SGLT2i trials?

Watch now Opens in new tab

PTPHF||Guidelines recommend the 4-pillar approach in managing HFrEF. What is a practical approach to implement this?

4:21

PTPHF||Guidelines recommend the 4-pillar approach in managing HFrEF. What is a practical approach to implement this?

Watch now Opens in new tab

Sitemap

Therapeutic Area

Resources
- Videos
- Clinical studies

BI logo

Privacy
Terms of use
Sitemap
Contact

This website is intended for healthcare professionals in Malaysia. The contents of this website are for information purposes only and are not intended to substitute for advice, treatment or recommendations of a healthcare professional. For your health concerns and other questions about symptoms, treatment or medication, consult a healthcare professional.

Copyright © 2025 Boehringer Ingelheim (Malaysia) Sdn Bhd.
All rights reserved. Use of this site is subject to the Terms of Use and Privacy Statement.